Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
InVaACS: Influenza Vaccination After Acute Coronary Syndrome
NCT07259252Recruiting
- Sponsor
- Tongji Hospital
- Start
- Dec 2025
- Primary completion
- Mar 2029
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Randomised trial in acute coronary syndrome (ACS) comparing Influenza vaccination with Placebo (2 arms). Primary endpoint: Composite endpoint of cardiovascular death, myocardial infarction or stroke at 12 months. Started Dec 2025; status: recruiting.
02
Drugs
influenza vaccine
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT07259252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07259252.